SIM0080

SIM0080 is an investigational oncology therapeutic being developed by Simcere Pharmaceutical (specifically its subsidiary Shandong Simcere Medgenn). It is described in company pipeline materials as targeting a serine/threonine kinase (STK) and is categorized as an antibody-drug conjugate (ADC). While some pipeline charts suggest a dual nature or ambiguity between a small-molecule inhibitor and an ADC, the primary classification in recent oncology contexts for this code name is an ADC targeting an STK. The drug is designed to deliver a potent cytotoxic payload directly to cancer cells expressing the target kinase, thereby minimizing systemic toxicity. It is currently in early-stage development for the treatment of various cancers.